Advertisement

Topics

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

08:27 EDT 14 Jun 2019 | pharmaphorum

Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just. Lilly reported last year that the SPIRIT-H2H trial had shown Ta...

Original Article: Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

NEXT ARTICLE

More From BioPortfolio on "Lilly’s Taltz scrapes win against Humira in psoriatic arthritis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....